The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms

被引:43
作者
Bolt, J
Vo, QN
Kim, WJ
McWhorter, AJ
Thomson, J
Hagensee, ME
Friedlander, P
Brown, KD
Gilbert, J
机构
[1] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, UF Shands Canc Ctr, Gainesville, FL 32610 USA
[3] LSU Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA USA
[4] LSU Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA USA
[5] LSU Hlth Sci Ctr, Dept Otolaryngol, New Orleans, LA USA
[6] LSU Hlth Sci Ctr, Sch Publ Hlth, New Orleans, LA USA
[7] LSU Hlth Sci Ctr, Dept Med, Infect Dis Sect, New Orleans, LA USA
[8] LSU Hlth Sci Ctr, Dept Med, Sect Hematol & Oncol, New Orleans, LA USA
关键词
HPV; SCCHN; ATM methylation; p53; mutation;
D O I
10.1016/j.oraloncology.2005.06.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ATM/p53 pathway plays a critical role in maintenance of genome integrity and can be targeted for inactivation by a number of characterized mechanisms including somatic genetic/epigenetic alterations and expression of oncogenic viral proteins. Here, we examine a panel of 24 SCCHN tumors using various molecular approaches for the presence of human papillornavirus (HPV), mutations in the p53 gene and methylation of the ATM promoter. We observed that 30% of our SCCHN samples displayed the presence of HPV and all but one was HPV type 16. All HPV E6 gene-positive tumors exhibited E6 transcript expression. We observed 21% of the tumors harbored p53 mutations and 42% of tumors displayed ATM promoter methylation. The majority of tumors (71%) were positive for at least one of these events. These findings indicate that molecular events resulting in inactivation of the ATM/p53 pathway are common in SCCHN and can arise by a number of distinct mechanisms. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1013 / 1020
页数:8
相关论文
共 30 条
[1]   Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma:: Promoter hypermethylation with clinical correlation in 100 cases [J].
Ai, LB ;
Quynh, NV ;
Zuo, CL ;
Li, LW ;
Ling, WH ;
Suen, JY ;
Hanna, E ;
Brown, KD ;
Fan, CY .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (01) :150-156
[2]  
Balz V, 2003, CANCER RES, V63, P1188
[3]   Aberrant methylation of gene promoters in cancer - Concepts, misconcepts, and promise [J].
Baylin, SB ;
Belinsky, SA ;
Herman, JG .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (18) :1460-1461
[4]   TP53 and head and neck neoplasms [J].
Blons, H ;
Laurent-Puig, P .
HUMAN MUTATION, 2003, 21 (03) :252-257
[5]   Sunlight and the onset of skin cancer [J].
Brash, DE .
TRENDS IN GENETICS, 1997, 13 (10) :410-414
[6]   Multiple ATM-dependent pathways: An explanation for pleiotropy [J].
Brown, KD ;
Barlow, C ;
Wynshaw-Boris, A .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 64 (01) :46-50
[7]  
Califano J, 1996, CANCER RES, V56, P2488
[8]   CAN A TEST FOR E6/E7 TRANSCRIPTS OF HUMAN PAPILLOMAVIRUS TYPE-16 SERVE AS A DIAGNOSTIC-TOOL FOR THE DETECTION OF MICROMETASTASIS IN CERVICAL-CANCER [J].
CZEGLEDY, J ;
IOSIF, C ;
HANSSON, BG ;
EVANDER, M ;
GERGELY, L ;
WADELL, G .
INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (03) :211-215
[9]   DETECTION OF NOVEL SPLICING PATTERNS IN A HPV16-CONTAINING KERATINOCYTE CELL-LINE [J].
DOORBAR, J ;
PARTON, A ;
HARTLEY, K ;
BANKS, L ;
CROOK, T ;
STANLEY, M ;
CRAWFORD, L .
VIROLOGY, 1990, 178 (01) :254-262
[10]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825